Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Analyzing timestamped EHR data from more than 21 million primary care visits in 2017, researchers have ascertained average lengths of visit and other metrics useful to assessing care quality.
Oxford researchers have developed and prospectively validated two AI tools that can quickly screen hospital patients for COVID-19 using routine clinical data.
North of the border, two grants of $200,000 are on offer for researchers innovating transformative ways to apply AI in healthcare—and they’re only one part of an ambitious academic endeavor to expand medical AI.
The COVID crisis has pushed healthcare providers to up their game on digital health, but the sector is not moving fast enough on this front for the liking of healthcare consumers.
More than 105 exhibitors presented AI-specific wares in the virtual AI showcase. That was down from 2019’s pre-COVID 150 but still easily beat 2018’s head count, around 75.
Drawing on nothing more than Facebook activity, psychiatric AI can distinguish individuals headed for hospitalization with schizophrenia from those with worsening mood disorders such as clinical depression and bipolar states.
A women’s health technology company has received the FDA’s blessing to market deep learning-based software designed to help breast radiologists spot hard-to-find nascent cancers in 3D mammograms.
Both outcomes and costs may vary widely from one patient to the next even in hospitals with consistently strong quality scores. Machine learning can help optimize the selection process for each patient as an individual.
Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.
The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.
As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”
